FDA expands approval for Eli Lilly's Jaypirca in untreated leukemia patients

The FDA approved an additional indication for Eli Lilly's Jaypirca (pirtobrutinib), allowing the company to market the drug as a first-line treatment for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a known 17p deletion. A clinical trial demonstrated superior progression-free survival.

Detected & updated continuously · Source: Nebula